135 related articles for article (PubMed ID: 10068269)
1. Can we cure indolent lymphomas?
Cabanillas F
Clin Cancer Res; 1997 Dec; 3(12 Pt 2):2655-9. PubMed ID: 10068269
[TBL] [Abstract][Full Text] [Related]
2. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
3. Bulky disease is an adverse prognostic factor in patients treated with chemotherapy comprised of cyclophosphamide, doxorubicin, vincristine, and prednisone with or without radiotherapy for aggressive lymphoma.
Wilder RB; Rodriguez MA; Ha CS; Pro B; Hess MA; Cabanillas F; Cox JD
Cancer; 2001 Jun; 91(12):2440-6. PubMed ID: 11413536
[TBL] [Abstract][Full Text] [Related]
4. The role of molecular monitoring in autotransplantation for non-Hodgkin's lymphoma.
Galimberti S; Marasca R; Caracciolo F; Fazzi R; Papineschi F; Benedetti E; Guerrini F; Morabito F; Oliva E; Di Renzo N; Federico M; Petrini M; Torelli G;
Bone Marrow Transplant; 2002 Apr; 29(7):581-7. PubMed ID: 11979307
[TBL] [Abstract][Full Text] [Related]
5. The role of mitoxantrone in the treatment of indolent lymphomas.
Hagemeister F; Cabanillas F; Coleman M; Gregory SA; Zinzani PL
Oncologist; 2005 Feb; 10(2):150-9. PubMed ID: 15709217
[TBL] [Abstract][Full Text] [Related]
6. [Treatment of primary mediastinal large B-cell lymphomas].
Schneider T; Tóth E; Molnár Z; Várady E; Deák B; Horváth A; Horváth GI; Eid H; Schneider K; Lovey J; Keresztes S; Esik O; Lengyel Z; Rosta A
Orv Hetil; 2004 Dec; 145(50):2531-7. PubMed ID: 15662753
[TBL] [Abstract][Full Text] [Related]
7. Phase II trial of sequential therapy with fludarabine followed by cyclophosphamide, mitoxantrone, vincristine, and prednisone for low-grade follicular lymphomas.
Rohatgi N; LaRocca RV; Bard V; Sethuraman G; Foon KA
Am J Hematol; 2002 Jul; 70(3):181-5. PubMed ID: 12111762
[TBL] [Abstract][Full Text] [Related]
8. Long-term follow-up of a prospective study of combined modality therapy for stage I-II indolent non-Hodgkin's lymphoma.
Seymour JF; Pro B; Fuller LM; Manning JT; Hagemeister FB; Romaguera J; Rodriguez MA; Ha CS; Smith TL; Ayala A; Hess M; Cox JD; Cabanillas F; McLaughlin P
J Clin Oncol; 2003 Jun; 21(11):2115-22. PubMed ID: 12775737
[TBL] [Abstract][Full Text] [Related]
9. Combination chemotherapy followed by an immunotoxin (anti-B4-blocked ricin) in patients with indolent lymphoma: results of a phase II study.
Longo DL; Duffey PL; Gribben JG; Jaffe ES; Curti BD; Gause BL; Janik JE; Braman VM; Esseltine D; Wilson WH; Kaufman D; Wittes RE; Nadler LM; Urba WJ
Cancer J; 2000; 6(3):146-50. PubMed ID: 10882329
[TBL] [Abstract][Full Text] [Related]
10. New treatment strategies in lymphomas: aggressive lymphomas.
Coiffier B
Ann Hematol; 2004; 83 Suppl 1():S73-4. PubMed ID: 15124681
[TBL] [Abstract][Full Text] [Related]
11. Follicular lymphoma in early stages: high risk of relapse and usefulness of the Follicular Lymphoma International Prognostic Index to predict the outcome of patients.
Plancarte F; López-Guillermo A; Arenillas L; Montoto S; Giné E; Muntañola A; Ferrer A; Villamor N; Bosch F; Colomo L; Balaguer O; Campo E; Montserrat E
Eur J Haematol; 2006 Jan; 76(1):58-63. PubMed ID: 16343272
[TBL] [Abstract][Full Text] [Related]
12. Novel treatment strategies in follicular lymphoma.
Buske C; Dreyling H; Unterhalt M; Hiddemann W
Ann Hematol; 2004; 83 Suppl 1():S72. PubMed ID: 15124680
[TBL] [Abstract][Full Text] [Related]
13. Hybrid chemotherapy consisting of cyclophosphamide, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, and vinblastine (C-MOPP/ABV) as first-line treatment for patients with advanced Hodgkin disease.
Montoto S; Camós M; López-Guillermo A; Bosch F; Cervantes F; Blandé J; Esteve J; Cobo F; Nomdedeu B; Campo E; Montserrat E
Cancer; 2000 May; 88(9):2142-8. PubMed ID: 10813727
[TBL] [Abstract][Full Text] [Related]
14. [Principles of treatment and military medical examination of the patients with indolent Non-Hodgkin's lymphomas].
Seriakov AP; Ushakov II; Ardashev VN; Mazurov VI; Korotkiĭ AN
Voen Med Zh; 2003 Oct; 324(10):34-41, 96. PubMed ID: 14671893
[TBL] [Abstract][Full Text] [Related]
15. Neuroblastoma.
Meir HM; Balawi I; Nayel H; Yousef MK; Badawood S; Al-Mobarak M
Saudi Med J; 2001 Aug; 22(8):674-80. PubMed ID: 11573111
[TBL] [Abstract][Full Text] [Related]
16. [Treatment option and outcome for patients with primary non-Hodgkin's lymphoma of the nasal cavity].
Yao B; Li YX; Song YW; Jin J; Liu YP; Wang WH; Wang SL; Sun YT; Yu ZH; Liu XF
Zhonghua Zhong Liu Za Zhi; 2006 Jan; 28(1):58-61. PubMed ID: 16737624
[TBL] [Abstract][Full Text] [Related]
17. Purine analogue combinations for indolent lymphomas.
Di Bella N; Ravandi F
Semin Hematol; 2006 Apr; 43(2 Suppl 2):S11-21. PubMed ID: 16549109
[TBL] [Abstract][Full Text] [Related]
18. Prognostic factors and treatment of patients with T-cell non-Hodgkin lymphoma: the M. D. Anderson Cancer Center experience.
Escalón MP; Liu NS; Yang Y; Hess M; Walker PL; Smith TL; Dang NH
Cancer; 2005 May; 103(10):2091-8. PubMed ID: 15816054
[TBL] [Abstract][Full Text] [Related]
19. CHOP plus rituximab chemoimmunotherapy of indolent B-cell lymphoma.
Czuczman MS
Semin Oncol; 1999 Oct; 26(5 Suppl 14):88-96. PubMed ID: 10561023
[TBL] [Abstract][Full Text] [Related]
20. The role of interferon in the therapy of malignant lymphoma.
McLaughlin P
Biomed Pharmacother; 1996; 50(3-4):140-8. PubMed ID: 8881370
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
